Tucidinostat
id:
tucidinostat-311-9777553
title:
Tucidinostat
text:
Tucidinostat is a histone deacetylase inhibitor (HDI) developed in China. It was also known as HBI-8000. It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan. In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021. Tucidinostat is being researched as a treatme
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Tucidinostat
date created:
date modified:
2024-02-08T04:51:40Z
main entity:
{"identifier":"Q19903814","url":"https://www.wikidata.org/entity/Q19903814"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/2/20/Tucidinostat.svg","width":1020,"height":385}
fields total:
13
integrity:
15